Want to see AU:IBX full AI Analyst Report?
IBX Stock Chart & Stats
AU$0.03
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.03
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.06
Previous CloseN/A
Volume347.18K
Average Volume (3M)16.05M
Market Cap
AU$5.89M
Enterprise ValueAU$4.25M
Total Cash (Recent Filing)AU$1.85M
Total Debt (Recent Filing)AU$2.56M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding490,590,240
10 Day Avg. Volume7,347,790
30 Day Avg. Volume16,053,124
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.21
Price to Sales (P/S)0.00
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary MagSense PlatformThe proprietary MagSense magnetic‑nanoparticle imaging platform represents a durable technological advantage. Owning a differentiated detection modality and related IP can create barriers to entry, enabling future licensing, partnerships and clinical differentiation if validation and regulatory progress continue.
Focus On Early Breast Cancer DetectionConcentrated focus on early breast‑cancer diagnostics aligns with structural healthcare demand for earlier, accurate detection and screening. A targeted clinical and regulatory pathway helps concentrate resources, improving the odds of adoption by screening programs and health systems if clinical trials succeed.
High Gross Margin In 2024Reported ~85% gross margin in 2024 suggests attractive unit economics for the diagnostic output. If commercialized at scale, high gross margins support long‑term profitability once fixed R&D and commercialization costs are absorbed, improving sustainability and future cash generation potential.
Bears Say
Zero Revenue In 2025Revenue falling to zero in 2025 shows lack of commercial traction and heightens execution risk. Without product sales the company must rely on external capital to fund trials and commercialization, increasing financing, dilution and project‑timing risk over the next several quarters.
Negative Equity Since 2023Negative shareholders’ equity since 2023 signals solvency stress and weak financial cushions. This condition limits borrowing capacity, undermines investor and lender confidence, and raises the probability of dilutive capital raises or restructuring if clinical or regulatory setbacks occur.
Persistent Negative Cash FlowConsistent negative operating and free cash flow, with ~A$4.0M burned in 2025 despite improvement, forces recurring financing. Ongoing cash burn increases dilution risk, may slow trial progress or commercialization, and constrains the company’s ability to invest strategically without external funding.
Imagion Biosystems Ltd. News
IBX FAQ
What was Imagion Biosystems Ltd.’s price range in the past 12 months?
Imagion Biosystems Ltd. lowest share price was AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is Imagion Biosystems Ltd.’s market cap?
Imagion Biosystems Ltd.’s market cap is AU$5.89M.
When is Imagion Biosystems Ltd.’s upcoming earnings report date?
Imagion Biosystems Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 65 days.
How were Imagion Biosystems Ltd.’s earnings last quarter?
Imagion Biosystems Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.
Is Imagion Biosystems Ltd. overvalued?
According to Wall Street analysts Imagion Biosystems Ltd.’s price is currently Overvalued.
Does Imagion Biosystems Ltd. pay dividends?
Imagion Biosystems Ltd. does not currently pay dividends.
What is Imagion Biosystems Ltd.’s EPS estimate?
Imagion Biosystems Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imagion Biosystems Ltd. have?
Imagion Biosystems Ltd. has 490,590,240 shares outstanding.
What happened to Imagion Biosystems Ltd.’s price movement after its last earnings report?
Imagion Biosystems Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.538%.
Which hedge fund is a major shareholder of Imagion Biosystems Ltd.?
Currently, no hedge funds are holding shares in AU:IBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imagion Biosystems Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IBX Sentiment 88%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.50%
12-Months-Change
Fundamentals
Return on Equity
142.99%
Trailing 12-Months
Asset Growth
-27.09%
Trailing 12-Months
Company Description
Imagion Biosystems Ltd.
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to magnetic relaxometry. The company has collaboration agreement with Wayne State University to develop optimised MRI sequences which is in Phase 2 study of for the MagSense imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in Melbourne, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Cryosite Limited
―
―
Inoviq Ltd
―
Options Prices
Currently, No data available
---